Dr. Abraham is a veteran leader in oncology research and development. Before Odyssey, Dr. Abraham served as Chief Scientific Officer at Vividion Therapeutics, which was acquired in August 2021 by Bayer for $2 billion. Previously, he held the position of Senior Vice President and Group Head of the Oncology R&D Group in Pfizer Worldwide Research, Development, and Medical. While at Pfizer, he helped launch 10 new oncology medicines, including XALKORI, IBRANCE, BESPONSA, BOSULIF, BAVENCIO, MYLOTARG, TALZENNA, DAURISMO, and LORBRENA, benefiting hundreds of thousands of patients worldwide. Dr. Abraham received his Ph.D. in Pharmacology from the University of Pittsburgh.
Current role